Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.

[1]  S. Yusuf,et al.  Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin , 2013, Circulation.

[2]  Petr Neuzil,et al.  Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). , 2013, Journal of the American College of Cardiology.

[3]  P. Neužil,et al.  Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients with Atrial Fibrillation: 2.3 Year Follow-Up of the PROTECT AF Trial , 2013 .

[4]  P. Neužil,et al.  Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation , 2013 .

[5]  Andrea Natale,et al.  Percutaneous Closure of the Left Atrial Appendage. , 2012, Cardiac electrophysiology clinics.

[6]  C. Granger,et al.  Newer Oral Anticoagulants Should Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation and Risk Factors for Stroke or Thromboembolism , 2012, Circulation.

[7]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[8]  S. Bertog,et al.  Percutaneous left atrial appendage closure , 2011, Herz.

[9]  Bernhard Meier,et al.  Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[10]  Saibal Kar,et al.  Safety of Percutaneous Left Atrial Appendage Closure: Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Registry , 2011, Circulation.

[11]  Donald R. Lynch.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[12]  D. Holmes.  Atrial fibrillation and stroke management: present and future. , 2010, Seminars in neurology.

[13]  J. Dunning,et al.  Best evidence topic - Cardiac general Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion? , 2010 .

[14]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[15]  Maurice Buchbinder,et al.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2009, The Lancet.

[16]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[17]  E. Blackstone,et al.  Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. , 2008, Journal of the American College of Cardiology.

[18]  E. Hylek,et al.  Reducing the risk for stroke in patients who have atrial fibrillation. , 2008, Cardiology clinics.

[19]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[20]  G. Schuler,et al.  Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. , 2007, Journal of the American College of Cardiology.

[21]  M. Pfeffer,et al.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.

[22]  Bernhard Meier,et al.  Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. , 2005, Journal of the American College of Cardiology.

[23]  D. Levy,et al.  Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study , 2004, Circulation.

[24]  Yuchiao Chang,et al.  Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? , 2003, JAMA.

[25]  M. Lesh,et al.  Percutaneous Left Atrial Appendage Transcatheter Occlusion to Prevent Stroke in High-Risk Patients With Atrial Fibrillation: Early Clinical Experience , 2002, Circulation.

[26]  R B D'Agostino,et al.  Stroke severity in atrial fibrillation. The Framingham Study. , 1996, Stroke.

[27]  J. Odell,et al.  Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. , 1996, The Annals of thoracic surgery.

[28]  David B. Dunson,et al.  Bayesian Data Analysis , 2010 .

[29]  P. Koudstaal.  Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. , 1995, The New England journal of medicine.

[30]  S M Nazarian,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.

[31]  M Gent,et al.  Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.

[32]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.